Image

    Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update

    Alia Abbas, Tyler Downing, Chiemelum Amechi … Boni Elewski
    Studysummary In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on skin.dermsquared.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Frontal Fibrosing Alopecia Shows Robust T Helper 1 and Janus Kinase 3 Skewing British journal of dermatology/British journal of dermatology, Supplement · 2020
    2. Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series Dermatologic therapy · 2018
    3. Frontal Fibrosing Alopecia: A Multicenter Review of 355 Patients Journal of The American Academy of Dermatology · 2014